Emma Andrus, Associate Editor

BoNT/E represents a novel approach in the world of neurotoxins, characterized by its rapid onset of action.

Helen Torok, MD, shares her atopic dermatitis insights.

Four grants were awarded for communities in communities in Miami-Dade County, Florida; Los Angeles County, California; rural communities in Oregon, and downtown Philadelphia, Pennsylvania.

Renata Block, MMS, PA-C, shares her atopic dermatitis insights.

Keep up with the latest headlines in dermatology from the past week, including the creation of a dermatology outreach organization centered in Detroit, a tropical skin disease endemic in parts of the US, and more.

The US Food and Drug Administration has approved IDP-126 gel for patients with acne.

The CRL states that additional efficacy data is needed in order to support approval.

82.8% of adult patients with iPsO achieved an IGA score of 0 or 1 indicative of complete or almost complete lesion clearance.

Skin clearance, itch relief, and reduced severity of atopic dermatitis were sustained with monthly maintenance dosing.

Topline results from the phase 3b trial revealed significant improvements in patients with skin of color whose psoriasis was treated with guselkumab.

Factors determining severe levels of stress included uncertainty about treatment progress, diagnosis, and treatment path.

Among the many sessions to be held at the 2023 Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Bimekizumab is now the first and only approved IL-17A and IL-17F inhibitor for this indication.

Allergan Aesthetics recently announced the fifth-year of its partnership with Girls Inc. Nkem Ugonabo, MD, MPH, and Adelle Infante recently spoke with Dermatology Times to discuss the importance of STEM and dermatology mentorship.

While blue light irradiation was efficacious in reducing itch and IL-31 levels, it did not reduce any of the objective measures of AD.

In studying pediatric patients with skin of color in a center specializing in pigment and skin of color, investigators described a paucity of literature of such nature.

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

The advancement is based on previous observations of preliminary clinical efficacy. There are currently no FDA-approved therapies for this patient population.

Inmagene recently announced the first patient was dosed in its study of the efficacy and safety of IMG-007 in hair loss.

In this Q&A, eczema patient, advocate, and "skinfluencer" Alexis Smith offers perspectives on National Eczema Awareness Month and AbbVie's Under My Skin documentary.

Keep up with the latest headlines in dermatology from the past week, including the use of AI to effectively detect skin cancers, research related to the burden of stigma in acne among women, and more.

Joel Schlessinger, MD, shares his atopic dermatitis insights.

UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year's EADV Congress.

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

Last week was Body-Focused Repetitive Behaviors Awareness Week. Related to dermatology, dermatillomania, also known as skin picking disorder, is a condition that requires empathy and understanding year round.

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.

Dermatologist Diego Ruiz Dasilva, MD, FAAD, and a patient with atopic dermatitis discuss the patient journey from initial symptoms to diagnosis to treatment selection.

This World Mental Health Day, Dermatology Times is reviewing the important and often comorbid mental health concerns linked to common dermatologic conditions.

The grant will go toward supporting the group's project, "Atopic Dermatitis is More Than a Skin Disease: Raising Awareness and Improving Care."